GlassScriptPhysician profile
David Dirk Vander Velde
NPI 1396743084
$894.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $225 · 2021: $506 · 2022: $22.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $197.54 | 2019-2021 | |
| Lundbeck LLC | $153.72 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $106.16 | 2019-2021 | |
| Abbvie INC. | $104.85 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $66.43 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $60.83 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $56.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.74 | 2019-2020 | |
| Eisai INC. | $40.19 | 2021 | |
| Agile Therapeutics, INC. | $35.86 | 2021 | |
| Allergan, INC. | $13.21 | 2020 | |
| Novo Nordisk INC | $12.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vander Velde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.